Get all your news in one place.
100's of premium titles.
One app.
Start reading
The Guardian - UK
The Guardian - UK
Science
Andrew Gregory Health editor in Chicago

Breast cancer drug cuts risk of most common form returning by 25%

Ribociclib may boost outcomes for patients with much earlier-stage breast cancer than previously shown.
Ribociclib may boost outcomes for patients with much earlier-stage breast cancer than previously shown. Photograph: Rui Vieira/PA

Thousands of women with the world’s most common form of breast cancer could benefit from a blockbuster drug that helps them live longer and cuts the risk of the disease returning by a quarter.

More than 2 million people globally are diagnosed each year with the disease, which is the world’s most prevalent cancer. Although treatments have improved in recent decades, many patients will later experience the cancer returning. If a recurrence does occur, it is often at a more advanced stage.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.